Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database

Chikako Shirai,1 Nobushige Matsuoka,2 and Toru Nakazawa3

Abstract

Purpose: This study evaluated Japanese patients’ adherence to first-line therapy and physicians’ compliance with the guidelines (GLs) for glaucoma in daily practice.

Methods: This retrospective, noninterventional cohort study used a Japanese health care/pharmacy claims database from 2011 to 2016. We compared adherence based on the primary outcomes assessed as proportion of days covered (PDC) and persistence between patients who received first-line monotherapy followed by second-line fixed-combination therapy (GL-compliant cohort) and those who received first-line fixed-combination therapy (GL-noncompliant cohort). Furthermore, we explored treatment patterns, glaucoma consultation, and key factors associated with GL noncompliance.

Results: Among 11,666 patients who received first-line therapy, 1,183 (10.1%) and 542 (4.6%) were in the GL-compliant and GL-noncompliant cohorts, respectively. Prostaglandin (70.7%) and subsequent prostaglandin/β-blocker (BB) (20.9%) within 12 months were most used by the GL-compliant cohort. Prostaglandin/BB (48.9%) and carbonic anhydrase inhibitor/BB (51.1%) were prescribed for the GL-noncompliant cohort. The mean PDC [standard deviation (SD)], persistence rate (95% confidence interval), and consultation (SD) over 12 months were 60.9% (34.0), 16.0% (14.0–18.1), and 5.23 (3.21) times, respectively, in the GL-compliant cohort and 59.7% (35.8), 22.0% (18.6–25.5), and 4.76 (3.19) times, respectively, in the GL-noncompliant cohort. No significant differences were observed between the 2 cohorts. No clinically relevant factor associated with GL noncompliance was found.

Conclusions: Around 5% of patients were prescribed a fixed-combination eye drop as first-line therapy not in accordance with GLs. The similarity of adherence and persistence between the 2 cohorts indicates that first-line fixed-combination therapy could be considered for glaucoma treatment.

Keywords: adherence, persistence, glaucoma, fixed-combination therapy, claims data, latanoprost

Introduction

Glaucoma is the most common causative disease of blindness in Japan. The proportion of patients with blindness caused by glaucoma increased to 28.6% in the fiscal year 2015 from previous surveys in the fiscal years 2007–2009.¹ Visual field deterioration can be prevented if glaucoma is detected at an early stage, and therapy is initiated soon after diagnosis.² However, the Tajimi Study, conducted by the Japan Glaucoma Society, showed that ~90% of glaucoma cases were undiagnosed despite a prevalence of 5.0% in Japanese people aged >40 years,³ indicating that therapy was not started in a timely manner.

The Japan Glaucoma Society Guidelines for Glaucoma (4th edition) state that reduction of intraocular pressure (IOP) is the only established treatment for primary open-angle glaucoma (broad definition of glaucoma), and the guidelines (GLs) recommend starting with a single drug (monotherapy) as first-line therapy, 2 drugs as second-line therapy, increasing by one drug each time, followed by laser
treatment or surgery. However, some patients may be better known that the disease may continue to progress during the late stages of glaucoma, even when treatment is provided. Accordingly, early detection and treatment of glaucoma are crucial. A recent study reported that selective laser trabeculoplasty was more cost-effective than eye drop treatment as a first-line therapy, although the medical costs vary from country to country.

Adherence to eye drops is clinically critical and is influenced by the number of eye drops used in daily practice. A previous 6-month observational trial reported that a fixed-combination (latanoprost/timolol) therapy led to a superior adherence rate and ocular surface health compared with unfixed-combination (latanoprost and timolol) therapy. Another randomized clinical trial demonstrated that fixed-combination therapy (travoprost/timolol) improved long-term adherence of patients with glaucoma compared with unfixed therapy (travoprost and timolol). Our database study also demonstrated that fixed-combination therapy was associated with greater adherence than unfixed therapy.

Specifically, latanoprost/timolol fixed-combination therapy for glaucoma has a high adherence rate. It lowers IOP more potently than unfixed-combination latanoprost or timolol monotherapy, and was developed with the aim of reducing the number of eye drops (reducing patient burden), avoiding the washout effect due to an inadequate interval of instillation time (reducing the drug’s efficacy), and reducing preservative exposure (reducing the risk of ocular surface disease). As such, fixed-combination eye drops have advantages in glaucoma treatment and can be used as a first-line therapy at the physician’s discretion in daily practice. However, since the release of the GLs, there have been no large-scale studies since in Japan on the state of GL compliance in clinical practice or adherence to first-line treatment.

Our primary objective was to compare patient adherence and persistence with first-line therapy between GL-compliant and GL-noncompliant cohorts using a Japanese administrative health care/pharmacy claims database. Secondary objectives were to explore physicians’ compliance with the GLs for glaucoma, the pattern of annual glaucoma treatment, incidence of annual glaucoma consultation, incidence of annual glaucoma surgery, and key factors associated with GL noncompliance.

Methods

Study overview and ethics

This retrospective, observational cohort study used a commercially available Japanese health care/pharmacy claims database to investigate the prescription status in daily practice. The database did not include data for glaucoma severity (eg, IOP, visual field, pathology) that may influence the treatment course of glaucoma (monotherapy or fixed-combination therapy as a first-line therapy). To address this limitation, we designed the distribution of glaucoma severity to be as comparable as possible between the cohorts. Therefore, data for patients with glaucoma who were newly prescribed a topical IOP lowering medication as a first-line therapy of either monotherapy followed by second-line fixed-combination therapy (GL-compliant cohort) or first-line fixed-combination therapy (GL-noncompliant cohort) were extracted and compared between the cohorts.

Since this study used only anonymized data from patients and did not use information linkable to individual identification, ethical approval and informed consent from the patients were not required according to the “Ethical Guidelines for Medical and Health Research Involving Human Subjects” set out by the Japanese government. This research project adhered to the tenets of the Declaration of Helsinki.

Data source and study cohort

The database was provided by MinaCare Co., Ltd., and secondary use of the data was permitted by each health insurance group. The MinaCare database contains anonymized data on both health checkup and medical/pharmacy claims of workers and their family members among a wide range of age groups <75 years. The database is regularly updated and has accumulated data since 2008 and, as of April 2017, included data from 6.3 million individuals, accounting for 1.7% of the Japanese population. Furthermore, it is generally consistent with 2 other national databases, and is useful as it has a low selection bias and a large sample size with a wide age distribution; however, it only targets large nationwide corporations and does not include individuals in primary industries or the self-employed.

Patients with International Classification of Diseases, 10th Edition (ICD-10) diagnosis codes H401 (normal tension glaucoma, primary open-angle glaucoma, and open-angle glaucoma) and H409 (unspecified glaucoma) were extracted from the database between April 1, 2011 and March 31, 2016. Patient identification (anonymized), age, sex, body weight, height, body mass index (BMI), smoking status, ICD-10 diagnosis codes, name/date of any prescribed drugs, hospital location, name of glaucoma medication class, name/date of glaucoma diagnosis tests, name/date of glaucoma-related surgery, and health checkup data, such as anthropometric measurements, blood pressure, blood glucose level, blood lipid level, liver function test values, hematologic values, and urine test results from the health checkup database, were also extracted. The index date was defined as the date of first prescription of topical IOP lowering medication for each patient, and the study was divided into 2 periods, before and after the index date, to determine newly prescribed medication for each patient. Among the extracted patients with glaucoma, eligible patients included those who did not receive glaucoma treatment in the preindex period for ~12 months, and thereafter had at least one record of prescription of topical glaucoma medication on or after the index date for ≥1 year. Topical glaucoma treatments included prostaglandin (PG) analog, β blocker (BB), carbonic anhydrase inhibitor (CAI), α2 receptor agonist (AA), α1 receptor blocker (AB), αβ blocker (ABB), cholinergic agonist, muscarinic agonist (MA), rho-associated coiled kinase inhibitor (ROCKI), fixed combinations and their generics. Patients with a history of glaucoma surgery, including laser treatment, on or before the index date were excluded.

The GL-compliant cohort was defined as patients who were newly prescribed a monotherapy as first-line therapy followed by a fixed-combination therapy as second-line therapy during the postindex period. Patients who switched to an unfixed-combination therapy were excluded. Patients who switched to other drug class monotherapies were considered adherent to first-line monotherapy. Patients who switched
to a combination therapy were considered to have discontinued their treatment to start second-line therapy, indicating that they required more potent or appropriate medication. In contrast, the GL-noncompliant cohort included patients with a fixed-combination therapy as first-line therapy. Patients who switched to an unfixed-combination therapy or monotherapy were considered to have discontinued their treatment.

**Study outcomes**

The primary outcomes of this study were adherence and persistence rates with the first-line topical glaucoma medication over the 12-month postindex period. Adherence was measured by the proportion of days covered (PDC) with medication. The *a priori* definition of the adherence cutoff point was 80%. Secondary outcomes were physicians’ compliance with the GLs for glaucoma, the pattern of annual glaucoma treatment, incidence of annual glaucoma consultation, and incidence of annual glaucoma surgery. The key factors associated with noncompliance to local GLs were also explored using patients’ demographic and clinical characteristics at the index date.

**Assessments**

Patient background characteristics included sex, age, body weight, height, BMI, smoking status/history, health checkup results, comorbidity, and residency region. Residency regions were classified into 8 regions from Hokkaido to Kyushu, including Okinawa,\(^{14}\) 2 areas (East Japan vs. West Japan),\(^{15}\) and city size (big cities including Tokyo and 20 ordinance-designated cities compared with the others).\(^{16}\) PDC was calculated for first-line topical glaucoma medication (monotherapy or fixed-combination therapy), regardless of switching to other drug classes. To address possible variations in dosage and the prescribed period reported on a claim for glaucoma medication, adjustments were made based on the unit volume of the formulation. For example, if the dosage was “7.5” and the period was “1” in a claim, this was converted to “2.5 mL (approved bottle) × 3 bottles” prescribed for 3 months, since one bottle (2.5 mL for once-daily formulations or 5 mL twice-or-more-daily formulations) is sufficient for application to one eye for >30 days but corresponds to 30 days dispensed. In Japan, the recommended use by period of an opened bottle of eye drops is generally 4 weeks. Accordingly, patients were permitted a 30-day grace period to obtain the next prescription. In addition, if one prescription consisted of ≥7 bottles, the patient was considered as receiving treatment for both eyes. The PDC value was calculated as follows:

\[
\text{PDC} \% = \left( \frac{\text{total prescription days during the 365-day assessment}}{365 \text{ days}} \right) \times 100.
\]

Persistence refers to the act of continuing index therapy (ie, first-line monotherapy or fixed-combination therapy). The definition of “persistence” is the duration in days from the index date (the first prescription date of the index therapy) to the last prescription date plus the number of prescription days or to the discontinuation date allowing a 30-day grace period. Treatment was considered as “discontinued” if there was no prescription record for >30 days or if the patient switched to second-line prescriptions. The cumulative discontinuation rate was analyzed based on the time to discontinuation and was estimated using the Kaplan–

![FIG. 1. Flowchart of the data extraction.](image-url)
### Table 1. Baseline Demographic and Clinical Characteristics of Subjects

| Variable                                      | GL-compliant cohort (N = 1183) | GL-noncompliant cohort (N = 542) |
|-----------------------------------------------|--------------------------------|----------------------------------|
|                                               | N  | Percentage or mean ± SD | n  | Percentage or mean ± SD |
| Sex, male (%)                                 | 666 | 56.3  | 322 | 59.4  |
| Age (years)                                   | 1183 | 52.6 ± 11.2 | 342 | 52.3 ± 12.4 |
| Body weight (kg)                              | 659 | 63.7 ± 12.8 | 295 | 64.3 ± 13.2 |
| Height (cm)                                   | 674 | 165.5 ± 8.8 | 302 | 165.6 ± 8.9 |
| Body mass index (kg/m²)                       | 659 | 23.1 ± 3.6 | 295 | 23.3 ± 3.8 |
| Smoking (%)                                   | 666 | 56.3  | 322 | 59.4  |
| Medication for other indications (%)          | 666 | 56.3  | 322 | 59.4  |
| Fasting blood glucose (mg/dL)                 | 632 | 99.0 ± 21.0 | 284 | 97.7 ± 17.1 |
| HbA1c (NGSP)                                  | 612 | 5.7 ± 0.8 | 277 | 5.6 ± 0.8 |
| Urine glucose (%)                             | 629 | 53.2  | 277 | 51.1  |
| Urine protein (%)                             | 600 | 50.7  | 277 | 51.1  |
| Antihypertensive drug (%)                     | 600 | 50.7  | 277 | 51.1  |
| Hypertension                                  | 294 | 24.9  | 139 | 25.6  |
| Coronary artery disease                       | 101 | 8.5  | 38 | 7.0  |
| Angina pectoris                               | 78 | 6.6  | 30 | 5.5  |
| Acute myocardial infarction                   | 20 | 1.7  | 5 | 1.0  |
| Ischemic heart disease                        | 54 | 4.6  | 27 | 5.0  |
| Heart failure                                 | 49 | 4.1  | 26 | 4.8  |
| Atherosclerosis or PAOD                       | 103 | 8.7  | 51 | 9.4  |
| Cerebral ischemia/chronic apoplexy           | 70 | 5.9  | 31 | 5.7  |
| Cerebral infarction                           | 43 | 3.6  | 23 | 4.2  |
| Venous veins of lower limb                    | 4 | 0.3  | 3 | 0.6  |
| Hyperlipidemia                                | 310 | 26.2 | 147 | 27.1 |
| Diabetes mellitus                             | 296 | 25.0 | 143 | 26.4 |
| Hypothyroidism                                | 90 | 7.6 | 38 | 7.0 |
| Water-electrolyte disorder                    | 66 | 5.6 | 38 | 7.0 |
| Mental disease or neurosis                    | 105 | 9.2 | 42 | 7.7 |
| Depression                                    | 48 | 4.1 | 23 | 4.2 |
| Insomnia                                      | 115 | 9.7 | 59 | 10.9 |
| Parkinson’s disease                           | 5 | 0.4 | 6 | 1.1 |
| Dementia                                      | 1 | 0.1 | 3 | 0.6 |
| Gastrointestinal ulcer                        | 135 | 11.4 | 62 | 11.4 |
| Nephropathy or chronic renopathy              | 42 | 3.6 | 25 | 4.6 |
| Kidney failure                                | 12 | 1.0 | 9 | 1.7 |
| Incontinence                                  | 1 | 0.1 | 1 | 0.2 |
| Hepatopathy                                   | 142 | 12.0 | 69 | 12.7 |
| Liver failure                                 | 1 | 0.1 | 1 | 0.2 |
| Pneumonia                                     | 42 | 3.6 | 12 | 2.2 |

(continued)
Table 1. (Continued)

| Variable                  | GL-compliant cohort (N=1183) | GL-noncompliant cohort (N=542) |
|---------------------------|------------------------------|-------------------------------|
|                           | N               | Percentage or mean ± SD       | n               | Percentage or mean ± SD       |
| Asthma or COPD            | 164             | 13.9                          | 92              | 17.0                          |
| Cancer                    | 337             | 28.5                          | 149             | 27.5                          |
| Anemia                    | 106             | 9.0                           | 37              | 6.8                           |
| Locations                 |                 |                               |                 |                               |
| 8 regions (%)             |                 |                               |                 |                               |
| Hokkaido                  | 33              | 2.8                           | 11              | 2.0                           |
| Tohoku                    | 36              | 3.0                           | 20              | 3.7                           |
| Kanto                     | 771             | 65.2                          | 362             | 66.8                          |
| Chubu                     | 84              | 7.1                           | 39              | 7.2                           |
| Kinki                     | 123             | 10.4                          | 60              | 11.1                          |
| Chugoku                   | 33              | 2.8                           | 14              | 2.6                           |
| Shikoku                   | 11              | 0.9                           | 6               | 1.1                           |
| Kyushu                    | 92              | 7.8                           | 30              | 5.5                           |
| Areas (%)                 |                 |                               |                 |                               |
| East Japan                | 859             | 72.6                          | 396             | 73.1                          |
| West Japan                | 324             | 27.4                          | 146             | 26.9                          |
| City size (%)             |                 |                               |                 |                               |
| Tokyo and all GODMCs      | 970             | 82.0                          | 455             | 83.9                          |
| Other than GODMCs         | 213             | 18.0                          | 87              | 16.1                          |

GL, guidelines; NGSP, National Glycohemoglobin Standardization Program; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; γ-GTP, γ-glutamyl transpeptidase; PAOD, peripheral arterial occlusive disease; COPD, chronic obstructive pulmonary disease; GODMCs, government ordinance-designed major cities.

**FIG. 2.** First-line drugs and treatment patterns over the 12-month postindex period. Drug class and generic names of first-line monotherapy (A) and treatment patterns (B) in the guideline-compliant cohort. Drug class and generic names of first-line fixed-combination therapy (C) and treatment patterns (D) in the guideline-noncompliant cohort. AA, α2 agonist; AB, α1 blocker; ABB, αβ blocker; BB, β blocker; Bzm, brinzolamide; CAI, carbonic anhydrase inhibitor; Car, carteolol; Dor, dorzolamide; Lat, latanoprost; MA, muscarinic agonist; PG, prostaglandin analog, ROCKI, rho-associated coiled kinase inhibitor; Taf, tafluprost; Tim, timolol; Tra, travoprost.
Meier method. Patients who continued the first-line treatment for 12 months were treated as censored at 12 months. The persistence rate at the evaluated time point was calculated as follows:

\[
\text{Persistence rate} = 100\% - \text{cumulative discontinuation rate}.
\]

The annual consultation rate was calculated as the number of eye examinations per patient for 12 months after the index date. The examinations were categorized into 3 groups: (1) general eye examination including ophthalmoscopy (retina, optic disk, and vitreous humor tests) and tonometry (IOP test); (2) perimetry (visual field test); and (3) optical coherence tomography.

**Statistical analysis**

Results were presented as mean and standard deviation (SD) or number and proportion of patients. The mean PDC for 12 months between 2 cohorts was compared using \( t \) test. In addition, the number and proportion (percentages) of patients in the following categories were identified by cohort: PDC \( \geq 0.8 \); PDC <0.8; 0.6 \( \leq \) PDC <0.8; 0.4 \( \leq \) PDC <0.6; 0.2 \( \leq \) PDC <0.4; and PDC <0.2. The proportion of patients with or without PDC \( \geq 0.8 \) between the 2 cohorts was compared using Pearson’s \( \chi^2 \) test.

**Results**

A total of 57,899 patients were diagnosed with glaucoma in the database (Fig. 1). After excluding 39,030 patients with <12 months preindex period or glaucoma surgery on or before the index date, we extracted 18,869 patients prescribed with an IOP lowering eye drop as first-line therapy and analyzed 11,666 patients who had at least one record.

**Table 2. Adherence to First-Line Therapy of the Guidelines-Compliant and -Noncompliant Cohorts During the 12-Month Postindex Period**

|                | All patients N=1725 | GL-compliant cohort N=1183 | GL-noncompliant cohort N=542 |
|----------------|---------------------|---------------------------|-----------------------------|
| PDC, mean±SD (%) | 60.5±34.6           | 60.9±34.0                 | 59.7±35.8                   |
| n (%)           |                     |                           |                             |
| 80+ % PDC       | 718 (41.6%)         | 483 (40.8%)               | 235 (43.4%)                 |
| 0.8; 0.6        | 1007 (58.4%)        | 700 (59.2%)               | 307 (56.6%)                 |
| <80 % PDC       | 190 (11.0%)         | 143 (12.1%)               | 47 (8.7%)                   |
| 0.4; 0.6        | 217 (12.6%)         | 170 (14.4%)               | 47 (8.7%)                   |
| 0.2; 0.4        | 251 (14.6%)         | 177 (15.0%)               | 74 (13.7%)                  |
| <0.2 % PDC      | 349 (20.3%)         | 210 (17.8%)               | 139 (25.6%)                 |

\( * \)-test between GL-compliant and -noncompliant cohorts.

\( # \)-test between GL-compliant and -noncompliant cohorts.

A \( P \) value <0.05/6 (=0.00833) was considered statistically significant (by Bonferroni correction).

Time (in days) to treatment switching or discontinuation over 12 months was analyzed using the Kaplan–Meier method, and the persistence rate at 6 and 12 months and the corresponding Wald 95% confidence intervals (CI) were calculated. In addition, differences in persistence were compared using the log-rank test. Patients who did not switch to other medications or did not discontinue first-line medication were censored on the last day of the 12th month in the postindex period.

Bonferroni correction was used to adjust for multiplicity (\( m=6 \), where \( m \) is the total number of statistical tests in this study). All \( P \) values >0.05/6 (=0.00833) were considered statistically significant for comparisons between cohorts.

Univariate logistic regression model was performed with subsequent multivariate analyses for those with \( P \) values <0.1, followed by variable selection using a stepwise manner to identify factors associated with GL noncompliance. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

**Table 3. Adherence to First-Line Latanoprost Therapy of the Subset of Switch from Latanoprost to Latanoprost/timolol in the Guideline-Compliant Cohort and to First-Line Latanoprost/timolol Therapy in the Noncompliant Cohorts During the 12-Month Postindex Period**

|                | All patients N=316 | Latanoprost N=189 | Latanoprost/timolol N=127 |
|----------------|---------------------|-------------------|---------------------------|
| PDC, mean±SD (%) | 65.3±33.5           | 62.9±32.8         | 68.8±34.3                 |
| n (%)           |                     |                   |                           |
| 80+ % PDC       | 147 (46.5%)         | 76 (40.2%)        | 71 (55.9%)                |
| 0.8; 0.6        | 169 (53.5%)         | 113 (59.8%)       | 56 (44.1%)                |
| <80 % PDC       | 36 (11.4%)          | 26 (13.8%)        | 10 (7.9%)                 |
| 0.4; 0.6        | 44 (13.9%)          | 34 (18.0%)        | 10 (7.9%)                 |
| 0.2; 0.4        | 40 (12.7%)          | 24 (12.7%)        | 16 (12.6%)                |
| <0.2 % PDC      | 49 (15.5%)          | 29 (15.6%)        | 20 (15.7%)                |

\( * \)-test (Latanoprost vs. Latanoprost/timolol).

\( # \)-test (Latanoprost vs. Latanoprost/timolol).

A \( P \) value <0.05/6 (=0.00833) was considered statistically significant (by Bonferroni correction).
of prescription of topical glaucoma medication on or after the index date for ≥1 year. Among these patients, 10,193 (87.4%) received a monotherapy as first-line therapy and 1,183 (10.1%) subsequently switched to fixed-combination eye drops as a second-line therapy (GL-compliant cohort). Meanwhile, 542 (4.6%) patients received fixed-combination eye drops as first-line therapy (GL-noncompliant cohort). In addition, 931 (8.0%) received other treatments such as unfixed-combination eye drops as first-line therapy.

The baseline demographics and clinical characteristics of the 2 cohorts were similar (Table 1). The mean age of the patients was 52 years, and most patients had a moderate BMI, nonsmoking habit, and normal values for glucose and lipid metabolism and liver function. In addition, 13%–14% of patients received medication for other indications. More than 20% of each cohort had comorbidities, including hypertension, hyperlipidemia, diabetes mellitus, and cancer. In both cohorts, >70% of patients lived in East Japan and >80% of patients lived in large cities.

The eye drops prescribed at the index date are summarized in Fig. 2. According to drug class, PG and BB were commonly prescribed in the GL-compliant cohort for 836 (70.7%) and 281 (23.8%) patients, respectively, whereas other treatments (ABB, CAI, AA, MA, and ROCKI) were rarely used (Fig. 2A). The top 3 commonly used eye drops according to generic name were latanoprost [389 (32.9%)], tafluprost [244 (20.6%)], and travoprost [164 (13.9%)] (Fig. 2A). Common treatment patterns from the index date to 12 months are shown in Fig. 2B. According to drug class, typical switching patterns were from PG to PG/BB [247 (20.9%), BB to CAI/BB [58 (4.9%)], and BB to PG/BB [34 (2.9%)]. In the GL-noncompliant cohort, CAI/BB [277 (51.1%) and PG/BB [265 (48.9%) were used by drug class, and the top 3 commonly used eye drops according to generic name were dorzolamide/timolol [229 (42.3%), latanoprost/timolol [127 (23.4%), and travoprost/timolol [110 (20.3%)] (Fig. 2C). The majority of patients received the same drug class over the 12-month postindex period. The proportion of the patients switching to other fixed-combination treatments was low (Fig. 2D).

Regarding the primary outcome of medication adherence, the mean PDC over the 12-month postindex period was 60.5% among all patients, 60.9% in the GL-compliant cohort, and 59.7% in the GL-noncompliant cohort (Table 2). High adherence (PDC ≥80%) was observed in 41.6% of all patients, 40.8% in the GL-compliant cohort, and 43.4% in the GL-noncompliant cohort. No significant difference was observed between the 2 cohorts. However, a comparison between the representative treatment patterns of the GL-compliant cohort and GL-noncompliant cohort (switching from latanoprost to latanoprost/timolol in the GL-compliant cohort, the latanoprost/timolol subset in the GL-noncompliant cohort showed a tendency toward higher persistence, but this did not reach statistical significance (Table 3).

As for the other primary outcome regarding persistence over 12 months, the Kaplan–Meier curves for the GL-compliant and noncompliant cohorts are presented in Fig. 3. Patients in the GL-compliant and noncompliant cohorts underwent general eye examinations 5.23 and 4.76 times on average for 12 months. In contrast, most patients in the GL-compliant (97.4%) and -noncompliant (97.8%) cohorts did not take a visual field test, and around half of the patients underwent optical coherence tomography once.
There was no tendency for the GL-compliant cohort to have more visits or better PDCs.

Glaucoma surgery was performed within 12 months after the index date for the first time in 15 patients (1.3%) in the GL-compliant cohort and 10 patients (1.8%) in the GL-noncompliant cohort, and the number of surgery cases was 0.42 and 0.71/100 person-years of observation (PYO), respectively. There were no marked differences in characteristics between 2 cohorts (Supplementary Table S1).

Univariate analyses between the 2 cohorts according to each baseline characteristic identified factors for GL noncompliance, including γ-glutamyl transpeptidase (γ-GTP) (P = 0.0205), and asthma or chronic obstructive pulmonary disease (P = 0.0921) (Table 5). Multivariate analyses using the factors obtained from univariate analyses followed by variable selection in a stepwise manner identified only γ-GTP [odds ratio: 1.003 per one unit increase (95% CI: 1.000–1.006), P = 0.0205] as a factor for GL noncompliance (Table 5). However, 95% CI of odds ratio included 1 and γ-GTP was measured in only ~60% of patients as shown in Table 1.

### Discussion

To date, there have been no studies on GL compliance of physicians in new patients with glaucoma in Japan or other countries. This study revealed that most Japanese patients with glaucoma were treated in accordance with the GLs, but ~5% of patients were prescribed a fixed-combination eye drop as first-line therapy. Although adherence to the therapy was moderate, there were no significant differences between the GL-compliant cohort and the GL-noncompliant cohort regarding the adherence and persistence to first-line therapy, annual glaucoma consultation, or annual glaucoma surgery. Therefore, first-line fixed-combination eye drops may be considered to be a convenient treatment option for glaucoma patients according to the patients’ medical needs, especially for those who are already at the severe glaucoma stage at the initial glaucoma consultation and need early IOP lowering treatment, those who are relatively young and for whom it is important to delay blindness, or those who need personalized medication due to their lifestyle.

According to the recommendation found in GLs as first-line treatment, PGs, such as latanoprost, tafluprost, or travoprost, were commonly prescribed. The most common
treatment pattern in the GL-compliant cohort over the 12-month postindex period was PG (33.1%) followed by PG switching to PG/BB (20.9%). However, few patients switched to other single drugs or add-on therapies. On the contrary, >70% of the GL-noncompliant cohort received CAI/BB (38.7%) and PG/BB (36.0%) over the 12-month postindex period.

The 12-month adherence to the first treatment was moderate in both cohorts and was similar between the 2 cohorts; the mean PDC was 60.9% in the GL-compliant cohort and 59.7% in the GL-noncompliant cohort at 12 months. Persistence over the 12-month postindex period did not differ, and the persistence rate of the first-line treatment was 16.0% in the GL-compliant cohort and 22.0% in the GL-noncompliant cohort. The persistence rates observed in this study were lower than those reported by a previous study (60.9%) in newly diagnosed Japanese patients. One possible explanation for these differences in the persistence rates is the differences in the definition of “discontinued.” In the previous study, the change of the initially prescribed glaucoma eye drops was not defined as “discontinued,” but it was defined so in this study. In the GL-compliant cohort, patients who switched to a fixed-combination therapy from a monotherapy as first-line therapy were considered to have discontinued their treatment. In the GL-noncompliant cohort, patients who switched to an unfixed-combination therapy or monotherapy from a fixed-combination therapy as first-line therapy were considered to have discontinued their treatment. Differences in the first dosing regimen (eg, single, unfixed combination, fixed combination) may be another reason for the differences among the studies’ results. In the previous study, 94.1% of new patients with glaucoma were medicated with single glaucoma eye drops; however, all the patients were medicated with a single (the GL-compliant cohort) or fixed combination (the GL-noncompliant cohort) in this study. Therefore, both studies evaluated different things; the previous study evaluated the persistence rate to total glaucoma medication use, whereas this study evaluated the persistence rate to the first-line glaucoma medication use. A systematic review summarized the results from 14 published studies focusing on the persistence with glaucoma medication use, and reported that only 31% of new patients with glaucoma remained persistent 12 months after starting therapy. Taken together, it is likely that patients in this study included those

| Ophthalmoscopy and tonometry | Perimetry | Optical coherence tomography |
|-----------------------------|-----------|------------------------------|
| **Mean (SD)**               | **Mean (SD)** | **Mean (SD)**                  |
| GL-CC (N=1183)             | GL-NC (N=542) | GL-CC (N=1183) | GL-NC (N=542) | GL-CC (N=1183) | GL-NC (N=542) |
| Mean (SD)                  | 5.23 ± 3.21 | 4.76 ± 3.19 | 0.05 ± 0.37 | 0.03 ± 0.25 | 1.11 ± 1.67 | 1.26 ± 1.80 |
| None, n (%)                | 83 (7.0%)  | 52 (9.6%)   | 1152 (97.4%) | 530 (97.8%) | 539 (45.6%) | 231 (42.6%)  |
| 1–3 times, n (%)           | 289 (24.4%) | 156 (28.8%) | 27 (2.3%)   | 12 (2.2%)   | 577 (48.8%) | 267 (49.3%)  |
| 4–6 times, n (%)           | 437 (36.9%) | 180 (33.2%) | 3 (0.3%)    | 0           | 45 (3.8%)  | 25 (4.6%)    |
| 7–9 times, n (%)           | 225 (19.0%) | 105 (19.4%) | 1 (0.1%)    | 0           | 11 (0.9%)  | 16 (3.0%)    |
| 10–12 times, n (%)         | 149 (12.6%) | 49 (9.0%)   | 0           | 0           | 11 (0.9%)  | 3 (0.6%)     |
| >12 times, n (%)           | 0          | 0           | 0           | 0           | 0          | 0             |

Ophthalmoscopy: test of the retina, optic disk, and vitreous humor. Tonometry: intraocular pressure test. Perimetry: visual field test. Optical coherence tomography: optical coherence tomography.

A P-value <0.05/6 (=0.00833) was considered statistically significant (by Bonferroni correction).
requiring a change in treatment plan due to relatively severe glaucoma stage at the index date or those who required early IOP lowering treatment.

Patients in both cohorts frequently received glaucoma consultations; the mean number of annual consultations with ophthalmoscopy and tonometry was 5.23 times in the GL-compliant cohort and 4.76 times in the GL-noncompliant cohort. A similar tendency was observed for other examinations.

Glaucoma surgery was observed to be performed at a certain rate in the GL-noncompliant cohort (0.71/100 PYO) and the GL-compliant cohort (0.42/100 PYO) for the 12-month postindex period. These surgery rates are likely due to the fact that patients who required early treatment but also required consideration of ocular allergy to eye drops, who had difficulty visiting the hospital, and who had cataract surgery were started with a fixed-combination drug and then immediately underwent surgery when they experienced difficulty in achieving reduction in IOP to prevent damage to the optic nerve.

No key factor was identified as being associated with GL noncompliance. This suggests that patients may be treated with either first-line monotherapy or fixed-combination therapy. Furthermore, physicians can consider prescribing fixed-combination agents according to the patient’s convenience depending on their characteristics, such as lifestyle and medication adherence. However, this study did not consider severity of glaucoma as these data were not available in the database. Although we compared data between newly diagnosed patients who were prescribed first-line monotherapy and those prescribed a fixed-combination therapy, it remains unclear whether there was a comparable distribution of severity of glaucoma among the 2 cohorts. Physicians may decide on a prescription according to the severity of the disease; however, a fixed-combination therapy would be appropriate since dual therapy is more effective than monotherapy.9,19

In conclusion, the patients' adherence and persistence to first-line therapy were not very high, but no significant differences were found between the GL-noncompliant cohort and the GL-compliant cohort. About 5% among all the physicians prescribed a fixed dose combination as first-line therapy, which did not comply with the GL. Furthermore, the annual incidence of glaucoma consultation or glaucoma surgery was similar. No factors associated with GL noncompliance were noted among newly diagnosed Japanese patients with glaucoma. Thus, fixed-combination eye drops

| Factors | Univariate P-value | Multivariate P-value | Odds ratio (95% CI) |
|---------|--------------------|----------------------|-------------------|
| Health care checkup values | | | |
| Sex 0.2253 | 0.9152 | | |
| Age 0.6073 | 0.8863 | 0.3827 | |
| Body weight 0.4984 | 0.1837 | 0.4904 | |
| Height 0.9605 | 0.517 | 0.9555 | |
| Body mass index 0.4070 | 0.2584 | 0.7423 | |
| Smoking 0.7936 | 0.7310 | 0.4960 | |
| Medication for other indication 0.9851 | 0.2273 | 0.9555 | |
| Fasting blood glucose | | | |
| HbA1c | | | |
| Urine glucose 0.8863 | 0.3827 | 0.9555 | |
| Urine protein 0.1837 | 0.4784 | 0.7423 | |
| Antihypertensive drug 0.4904 | 0.7423 | 0.4960 | |
| Systolic blood pressure 0.9555 | 0.7423 | 0.9555 | |
| Diastolic blood pressure 0.7423 | 0.4904 | 0.7423 | |
| Total cholesterol 0.4904 | 0.6899 | 0.4904 | |
| Triglycerides 0.5517 | 0.6899 | 0.4904 | |
| HDL-C 0.5517 | 0.6899 | 0.4904 | |
| LDL-C 0.2584 | 0.7310 | 0.4904 | |
| Aspartate aminotransferase | | | |
| Alanine aminotransferase | | | |
| γ-GTP 0.0205 | 0.999 | 1.003 (1.000–1.006) | |
| Locations | | | |
| 47 prefectures 0.9060 | | | |
| 8 regions 0.7315 | | | |
| East and West Japan 0.8456 | | | |
| City size 0.3207 | | | |
| Common comorbidities | | | |
| Hypertension 0.7231 | | | |
| Coronary artery disease 0.2804 | | | |
| Angina pectoris 0.4002 | | | |
| Acute myocardial infarction 0.2223 | | | |
| Ischemic heart disease 0.1168 | | | |
| Cardiac arrhythmia 0.7041 | | | |
| Heart failure 0.5361 | | | |
| Atherosclerosis or PAOD 0.6347 | | | |
| Cerebral ischemia/chronic apoplexy 0.8719 | | | |
| Cerebral infarction 0.5411 | | | |
| Hyperlipidemia 0.6874 | | | |
| Diabetes mellitus 0.5465 | | | |
| Hypothyroidism 0.6608 | | | |
| Water-electrolyte disorder 0.2470 | | | |
| Mental disease or neurosis 0.4369 | | | |
| Depression 0.8556 | | | |
| Insomnia 0.4562 | | | |
| Parkinson's disease 0.1108 | | | |

| Factors | Univariate P-value | Multivariate P-value | Odds ratio (95% CI) |
|---------|--------------------|----------------------|-------------------|
| Gastrointestinal ulcer 0.9867 | | | |
| Nephropathy or chronic renopathy 0.2905 | | | |
| Kidney failure 0.2606 | | | |
| Hepatopathy 0.6688 | | | |
| Liver failure 0.5808 | | | |
| Pneumonia 0.1431 | | | |
| Asthma or COPD 0.0921 | | | |
| Cancer 0.6707 | | | |
| Anemia 0.1369 | | | |

CI, confidence interval.

(continued)
could be used as first-line therapy as well as second-line therapy for glaucoma. A first-line fixed-combination option would be useful for personalized medication in view of severity of glaucoma in addition to improvement of adherence and health care by understanding patient preferences in daily practice.

Acknowledgment
We thank medical writer Takahiko Murata, PhD, WysiWyg Co., Ltd. for his assistance in the preparation of this article.

Author Disclosure Statement
Chikako Shirai and Nobushige Matsuoka are full-time employees of Pfizer Japan, Inc. and Pfizer R&D Japan G.K., respectively. Toru Nakazawa is a Professor of Tohoku University Graduate School of Medicine and has no conflicts of interest associated with this article.

Funding Information
This study was financially supported by Pfizer Japan, Inc. The authors are grateful to Yuji Yamamoto, MD, MBA, MinaCare Co., Ltd for supplying the data for this study.

Supplementary Material
Supplementary Table S1

References
1. Morizane, Y., Morimoto, N., Fujiiwara, A., et al. Incidence and causes of visual impairment in Japan: the first nationwide complete enumeration survey of newly certified visually impaired individuals. Jpn. J. Ophthalmol. 63:26–33, 2019.
2. Jonas, J.B., Aung, T., Bourne, R.R., et al. Glaucoma. Lancet. 390:2183–2193, 2017.
3. Iwase, A., Suzuki, Y., Araie, M., et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 111:1641–1648, 2004.
4. The Japan Glaucoma Society Guidelines for Glaucoma (4th Edition). Nippon Ganka Gakkai Zasshi. 2018; 122: 5–53. www.nichigan.or.jp/member/guideline/glaucomaa4.pdf. Last accessed on August 13, 2020. (in Japanese).
5. Gazzard, G., Konstantakopoulou, E., Garway-Heath, D., et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 393:1505–1516, 2019.
6. Boboridis, K.G., Konstas, A.G., Tounamidou, V., et al. Association for research in vision & ophthalmology ARVO Annual Meeting Abstract. Invest. Ophthalmol. Vis. Sci. 2012; 53:8238–8239.
7. Barnebey, H.S., and Robin, A.L. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am. J. Ophthalmol. 176:61–69, 2017.
8. Shirai, C., Matsuoka, N., Nakazawa, T. Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: A retrospective non-interventional cohort study. BMC Ophthalmol. 2021 [In press].
9. Higginbotham, E.J., Feldman, R., Stiles, M., and Dubiner, H. Latanoprost and timolol combination therapy vs monotherapy; one-year randomized trial. Arch. Ophthalmol. 120: 915–922, 2002.
10. The Ministry of Education, Culture, Sports, Science and Technology of Japan, the Ministry of Health, Labour and Welfare of Japan. Ethical guidelines for medical and health research involving human subjects: www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkankoukouseikagaku/0000080278.pdf. Last accessed on August 13, 2020.
11. Shima, D., Ii, Y., Yamamoto, Y., et al. A retrospective, cross-sectional study of real-world values of cardiovascular risk factors using a healthcare database in Japan. BMC Cardiovasc. Disord. 14:120, 2014.
12. Yuasa, A., Murata, T., Imai, K., Yamamoto, Y., and Fujimoto, Y. Treatment procedures and associated medical costs of methicillin-resistant Staphylococcus aureus infection in Japan: a retrospective analysis using a database of Japanese employment-based health insurance. SAGE Open Med. 7:2050312119871181, 2019.
13. Pharmacoepidemiology & Database Taskforce, Japanese Society for Pharmacoepidemiology. Databases available for pharmacoepidemiology researches in Japan (information obtained from suvey answers as of August 2019). Last accessed on August 24, 2020. www.jspe.jp/mt-static/FileUpload/files/JSPE_DB_TF_E.pdf.
14. Reardon, G., Kotak, S., and Schwartz, G.F. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 5:441–463, 2011.
15. Higginbotham, E.J. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin. Ophthalmol. 4:1–9, 2010.

Received: September 7, 2020
Accepted: November 5, 2020

Address correspondence to:
Dr. Toru Nakazawa
Department of Ophthalmology
Tohoku University Graduate School of Medicine
I–I Seiryo-machi, Aoba-ku
Sendai 980–8574
Japan

E-mail: ntoru@oph.med.tohoku.ac.jp